etoposide has been researched along with plerixafor in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Abdel-Rahman, FA; Tuffaha, H | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Armistead, PM; Brown, PM; Coghill, JM; Essenmacher, A; Gabriel, DA; Goyal, R; Irons, R; Rao, KV; Sarantopoulos, S; Serody, JS; Sharf, A; Shea, TC; Whitley, J; Wood, WA | 1 |
| Armistead, PM; Chow, E; Coghill, J; Covington, D; Gabriel, DA; Jamieson, KJ; Park, YA; Rao, KV; Raval, JS; Serody, JS; Shea, TC; Wood, WA | 1 |
| Craig, MD; Cumpston, A; D'Souza, A; Dhakal, B; Eastwood, D; Esselman, J; Fenske, TS; Hamadani, M; Hari, P; Kanate, AS; Pasquini, MC; Shillingburg, A; Veltri, LW; Watkins, K | 1 |
| Dimitriadis, GK; Kosmas, C; Miltiadous, C; Roditis, P | 1 |
| Braun, F; Burger, M; Catusse, J; Kayser, G; Reichardt, W; Taromi, S; von Elverfeldt, D; Weber, WA; Zeiser, R | 1 |
| Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
1 review(s) available for etoposide and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for etoposide and plerixafor
| Article | Year |
|---|---|
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation | 2017 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
8 other study(ies) available for etoposide and plerixafor
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor.
Topics: Antineoplastic Agents; Benzylamines; Carboplatin; Cyclams; Etoposide; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2010 |
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2013 |
Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization.
Topics: Adult; Aged; Algorithms; Benzylamines; Blood Component Removal; Cyclams; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Transplantation, Autologous; Young Adult | 2014 |
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Transfusion; Carboplatin; Cyclams; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Young Adult | 2016 |
Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation: report
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Carboplatin; Cyclams; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphatic Metastasis; Male; Neoplasms, Germ Cell and Embryonal; Thiotepa | 2017 |
CXCR4 antagonists suppress small cell lung cancer progression.
Topics: Animals; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cisplatin; Cyclams; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Heterocyclic Compounds; Humans; Lung Neoplasms; Mice; Mice, Knockout; Neoplasm Metastasis; Nuclear Proteins; Peptides; Receptors, CXCR4; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |